MedTrace Logo

Growth Hormone's Effect on the Cardiovascular System

NCT00397319 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2007-07-03

No results posted yet for this study

Summary

To evaluate specific markers of cardiovascular risk before and after growth hormone replacement therapy in a population of growth hormone deficient adults, as compared to an age, gender, and BMI-matched healthy population.

Conditions

  • Growth Hormone Deficiency

Interventions

DRUG

Growth Hormone

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Doug Vaughan, MD · Vanderbilt University Medical Center

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-08-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00397319 on ClinicalTrials.gov